Our work, together with previous studies (7, 15), supports the idea that therapies that reactivate Notch1 in T-cells could be used to tune T-cells against tumor-induced immunosuppression and enhance anti-cancer immune responses (Figure 9). The gene discussed is NOTCH1; the disease is neoplasm.